CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Accounting Officer & VP sold 1,871 shares at $0.98 ($1,834)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Shares withheld for taxes Chief Accounting Officer & VP gave up 1,640 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Accounting Officer & VP gave up 1,520 shares (to pay taxes)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Shares withheld for taxes Chief Accounting Officer & VP gave up 1,529 shares (to pay taxes)
- 4 Shares withheld for taxes EVP, Preclinical Development gave up 10,920 shares (to pay taxes)
- 4 Open-market sale Chief Legal & Adm. Officer sold 10,800 shares at $2.86 ($30,923)
- 4/A Grant or award Chief Medical Officer acquired 170,354 shares (grant or award)
- 4/A Grant or award Chief Executive Officer acquired 216,322 shares (grant or award)
Page 5 of 11 · 211 filings